Presentation is loading. Please wait.

Presentation is loading. Please wait.

ΕΚΕ 2012 1 Hellenic PCI Registry (2008-2011) Περιεχόμενο και αναγκαιότητα διατήρησης Registry Αγγειοπλαστικής Georgios.

Published byRudolf Simon Modified over 9 years ago

Similar presentations

Presentation on theme: "ΕΚΕ 2012 1 Hellenic PCI Registry (2008-2011) Περιεχόμενο και αναγκαιότητα διατήρησης Registry Αγγειοπλαστικής Georgios."— Presentation transcript:

1 ΕΚΕ 2012 1 Hellenic PCI Registry (2008-2011) Περιεχόμενο και αναγκαιότητα διατήρησης Registry Αγγειοπλαστικής http://registry.hellenicpci.gr/ Georgios I. Papaioannou, MD, MPH, FACC, FSCAI Athens Medical Center Cardiac Catheterization Laboratory 18/2/2012

2 ΕΚΕ 2012 2 Aim of the Hellenic PCI Registry (2008-2011) Common link with ESC (ESC PCI Registry) and EAPCI Recording of Centers/Operators/ Interventional Coronary Procedures with regional and national analyses Recording of basic indications, demographic, procedural and outcomes data of patients undergoing PCI National database for educational and professional requirements (in accordance to ESC/ACC) Quality and Outcomes Research

3 ΕΚΕ 2012 3 Registries & Clinical Practice

4 ΕΚΕ 2012 4 Timetable of the PCI Registry 5/2006:WG decision 7/2006:Funding for the initial phase 9/2006:Collaboration with Philip Lees (Webmaster) 12/2006:Early design of database 3/2007:Testing version in a separate domain (Phase I) 7/2007:Phase II – Pilot cases entry (>300 patients, 9 centers) 2/2008:Phase III – Official start of Registry retrospectively from 1/1/2008 with a 3-5 year plan (>2500 patients entered so far) 2/2011:3 year completion – Analyses of more than 4000 entries (National/Hospital/User level)

5 ΕΚΕ 2012 5 Tables (8) Patient (Automatic entry ID-Demographics-Patient initials) Workup (History-Risk factors-Indication-Times-Admission Medications) PCI Angiogram (Angiographic findings based on the 15- segment model of ESC) PCI Procedure (Periprocedural medications-Additional diagnostic or theurapeutic devices-Complications) PCI Lesions (Lesion characteristics-PCI device-Result) Outcome (In-hospital outcome) Follow up (1 year/3 years/5 years) Submit (Automatic initial validation)

6 ΕΚΕ 2012 6 PCI Centers: 2011

7 ΕΚΕ 2012 7 COR Procedures 2007-2010

8 ΕΚΕ 2012 8 PCI Procedures 2007-2010

9 ΕΚΕ 2012 9 PCI Volume per Center: 2007-2009 20072009

10 ΕΚΕ 2012 10 Primary PCI numbers: 2007-2011 * 2011: Estimated numbers

11 ΕΚΕ 2012 11 Hellenic PCI Registry (2/2008-10/2010) n=3441 validated patients: Demographics Males2859 (83.1%) Females582 (16.9%) Age64.1 ± 11.1 Height169.8 ± 10.8 Weight81.9 ± 14.9 BMI27.9 ± 3.9

12 ΕΚΕ 2012 12 Hellenic PCI Registry (2/2008-10/2010) n=3441 patients: Demographics Hx Stable Angina 877 (25.5%) Hx Prior MI 797 (23.2%) Hx CVA 56 (1.6%) Hx PVD 171 (4,9%) Hx of CRF 83 (2.4%) Hx Prior PCI 726 (21.1%) Hx Prior CABG 225 (9.1%) Current Smokers 1337 (38.9%) Former Smokers 1079 (31.4%) Current Diabetes 1029 (29.9%) Oral Agents - IDDM 601 - 172 (17.5% - 4.9%) Hypertension 2392 (69.5%) Dyslipidemia 2311 (67.1%)

13 ΕΚΕ 2012 13 Hellenic PCI Registry (2/2008-10/2010) n=3441 patients: PCI Indication Elective PCI*1622 (47.1%) ACS (UA/NSTEMI) 441 (12.8%) STEMI284 (8.3%) ACS stabilized622 (18.1%) STEMI stabilized 458 (13.3%) Other14 (0.4%) *Stable angina/documented ischemia

14 ΕΚΕ 2012 14 Hellenic PCI Registry (2/2008-10/2010) n=742 STEMI patients: Type of Therapy Thrombolysis prior PCI267 (35.9%) Primary PCI225 (30.3%) Delayed PCI517 (69.7%)

15 ΕΚΕ 2012 15 Hellenic PCI Registry (2/2008-10/2010) n=225 STEMI Primary PCI Patients: Times Mean symptom to door (min)249 Mean door to balloon (min)140 Door to balloon < 120 min147 (65.3%) Door to balloon < 90 min130 (57.7%)

16 ΕΚΕ 2012 16 Hellenic PCI Registry (2/2008-10/2010) n=3441 patients: Angio Data EF >50% 2460 (71.5%) 30%  EF  50% 647 (18.7%) EF<30% 84 (2.5%) EF Unknown 250 (7.3%) LM>50% 93 (2.7%) 1VD 1754 (51%) 2VD 1087 (31.6%) 3VD 598 (17.4%) Cardiogenic Shock 18 (0.5%) Treated LM 67 (1.2%) Treated LAD* 2189 (39.6%) Treated CX* 1440 (26.1%) Treated RCA* 1825 (33.1%) Treated by-pass graft 116 (2.1%) *Lesions

17 ΕΚΕ 2012 17 Hellenic PCI Registry (2/2008-10/2010) n=3441 patients: PCI Data Femoral Access3299 (95.9%) Radial Access109 (3.2%) IVUS74 (2.2%) Pressure wire67 (1.9%) IABP7 (0.2%) Distal Protection17 (0.5%) Thrombectomy150 (4.3%) Vascular closure device1135 (32.9%)

18 ΕΚΕ 2012 18 Hellenic PCI Registry (2/2008-10/2010) n=3441 patients – 5521 Lesions: PCI Data Type A lesion 637 (11.5%) Type B lesion 3454 (62.6%) Type C lesion 1430 (25.9%) Restenosis - Bifuraction 197 - 799 (3.6% - 14.5%) Direct stenting 876 (15.9%) PCI with stent 5161 (93.5%) Mean number stent(s) per patient 1.74 Mean number stent(s) per lesion 1.14 Mean stent size (mm) 3.08 Mean stent length (mm) 22.08 Multi-segment PCI 3517 (63.7%) Successful PCI 5378 (97.4%) BMS stenting* 1060 (19.2%) DES stenting* 4097 (74.2%) * Stent not specified: 362 (6.6%)

19 ΕΚΕ 2012 19 Hellenic PCI Registry (2/2008-10/2010) n=3441 patients: Concurrent PCI Management Clopidogrel prior PCI 2051 (59.6%) --- 300 mg 1765 (51.3%) --- 600 mg 286 (8.3%) --- <6 hrs 626 (30.5%) --- >6 hrs 1425 (59.5%) Clopidogrel during PCI 1364 (39.6%) --- 300 mg 857 (62.8%) --- 600 mg 507 (37.2%) GIIbIIIa inhibitors (upstream) 99 (2.9%) GIIbIIIa inhibitors (procedural) 383 (11.1%)

20 ΕΚΕ 2012 20 Hellenic PCI Registry (2/2008-10/2010) n=3441 patients: Complications & Outcomes Periprocedural complications 105 (3.1%) Acute segment closure 21 (0.6%) Side branch occlusion 28 (0.8%) Distal embolization 12 (0.3%) Coronary perforation 13 (0.4%) No flow/slow flow 31 (0.9%) In hospital death 18 (0.5%)* Periprocedural MI 35 (1.0%)* Periprocedural CVA 15 (0.4%) MACE (Death/MI/CVA) 65 (1.9%) Stent thrombosis 15 (0.4%) Repeat PCI 16 (0.5%) Emergency CABG 4 (0.1%) Major bleed 21 (0.6%) Renal failure 11(0.3%) * 1.2% ESC PCI Registry for Death and MI

21 ΕΚΕ 2012 21 Hellenic PCI Registry (2009-2010) n=2191 validated patients: Outcomes* Death15 (0.7%) Myocardial Infarction22 (1.0%) CVA9 (0.4%) MACE44 (2.0%) *Improved reporting of outcomes (mainly death) as Registry evolves – Pending non-validated entries in 2010 with outcomes

22 ΕΚΕ 2012 22 Registry General Issues National vs Regional “Selective” National “Selective” Regional Individual Hospital –Type of information / patients (?ACS only) –Amount of information –Obligation of filling

23 ΕΚΕ 2012 23 Financial Issues

24 ΕΚΕ 2012 24 Registry Benefits Data on all patients having PCI Data on ACS – Stent-for-life initiative Type of care – Areas of improvement in ACS patients Number of operators – Hospitals with Cath Lab facilities – Regional differences Type of interventional procedures (expanding to non-coronary cases too)

25 ΕΚΕ 2012 25 Difficulties & Problems Motivation of physicians (multifactorial) Politics Clear understanding of the role and the benefits of the registry with broad participation in analyses Establish a structure especially in high-volume centers for secretarial help Loss of enthusiasm of existing users if a wide participation can not be achieved

26 ΕΚΕ 2012 26 2012 Proposal to WG Continue keeping the existing structure of the Database (web site – server) with full- time professional(s) Complete a 3 year recording (2/2011) (done already) Establish software for National/Center/User analysis of entries (in plan) Decision regarding a “Selective” National Registry with aim to cover representative patients/data across the whole country

27 ΕΚΕ 2012 27 Participating Hospitals (>20 entries) *Top 3 Hospitals

28 ΕΚΕ 2012 28 Participating Physicians (Alphabetic order >10 entries) *Top 3 Physicians

Download ppt "ΕΚΕ 2012 1 Hellenic PCI Registry (2008-2011) Περιεχόμενο και αναγκαιότητα διατήρησης Registry Αγγειοπλαστικής Georgios."

Similar presentations

Introduction Recent guidelines considered PCI to be a potential alternative to CABG for ULMCA stenosis, based on several large registries and randomized.

Introduction Recent guidelines considered PCI to be a potential alternative to CABG for ULMCA stenosis, based on several large registries and randomized.
Distal Protection: PRIDE, CAPTIVE Symbiot III, AiMI Dr James Cotton MD MRCP Heart and Lung Centre Wolverhampton.

Distal Protection: PRIDE, CAPTIVE Symbiot III, AiMI Dr James Cotton MD MRCP Heart and Lung Centre Wolverhampton.
A Risk Score for Predicting Coronary Artery Bypass Surgery in Patients with Non-ST Elevation Acute Coronary Syndromes Sai Sadanandan, MD*; Christopher.

A Risk Score for Predicting Coronary Artery Bypass Surgery in Patients with Non-ST Elevation Acute Coronary Syndromes Sai Sadanandan, MD*; Christopher.
CPORT- E Trial Randomized trial comparing medical, economic and quality of life outcomes of non-primary PCI at hospitals with and without on-site cardiac.

CPORT- E Trial Randomized trial comparing medical, economic and quality of life outcomes of non-primary PCI at hospitals with and without on-site cardiac.
Complications of HSRA Layth A. Mimish Consultant Cardiologist Cardiovascular Consultants Group Jeddah, Saudi Arabia.

Complications of HSRA Layth A. Mimish Consultant Cardiologist Cardiovascular Consultants Group Jeddah, Saudi Arabia.
BWGIC survey Victor Legrand Yves Taeymans. PCI 2004 : procedures n= 23426.

BWGIC survey Victor Legrand Yves Taeymans. PCI 2004 : procedures n=
STEMI Due to Stent Thrombosis: An Enlarging Subgroup of High Risk Patients Bruce Brodie, Adam Bensimhon, Nathan Fleishman, Charles Hansen, Mike Cooper,

STEMI Due to Stent Thrombosis: An Enlarging Subgroup of High Risk Patients Bruce Brodie, Adam Bensimhon, Nathan Fleishman, Charles Hansen, Mike Cooper,
Raising the standard in treating bifurcation lesions GENNARO SARDELLA MD, FACC,FESC O.U. of Interventional Cardiology Dept. of.

Raising the standard in treating bifurcation lesions GENNARO SARDELLA MD, FACC,FESC O.U. of Interventional Cardiology Dept. of.
Francesco Liistro Cardiovascular Department, Arezzo, Italy Impact of Thrombus Aspiration on Myocardial Tissue Reperfusion and Left Ventricular Functional.

Francesco Liistro Cardiovascular Department, Arezzo, Italy Impact of Thrombus Aspiration on Myocardial Tissue Reperfusion and Left Ventricular Functional.
WG 2010 1 Hellenic PCI Registry Organization - Structure - Directions - Initial Recordings Georgios I. Papaioannou, MD,

WG Hellenic PCI Registry Organization - Structure - Directions - Initial Recordings Georgios I. Papaioannou, MD,
Chaim Lotan MD, Yaron Almagor MD, Karel Kuiper MD, M.J. Suttorp MD, William Wijns MD The SICTO Study CYPHER TM Sirolimus-eluting stent in Chronic Total.

Chaim Lotan MD, Yaron Almagor MD, Karel Kuiper MD, M.J. Suttorp MD, William Wijns MD The SICTO Study CYPHER TM Sirolimus-eluting stent in Chronic Total.
Around-the-Clock Primary Angioplasty: A Process of Care Analysis Comparing Off-Hours and Normal Hours Treatment of Acute STEMI R Leung, D Lundberg, D Galbraith,

Around-the-Clock Primary Angioplasty: A Process of Care Analysis Comparing Off-Hours and Normal Hours Treatment of Acute STEMI R Leung, D Lundberg, D Galbraith,
ACS and Thrombosis in the Emergency Setting

ACS and Thrombosis in the Emergency Setting
SCAAR UCR SWEDEN 2007 Stefan James, Jörg Carlsson, Johan Lindbäck, Tage Nilsson, Ulf Stenestrand, Lars Wallentin and Bo Lagerqvist for the SCAAR study.

SCAAR UCR SWEDEN 2007 Stefan James, Jörg Carlsson, Johan Lindbäck, Tage Nilsson, Ulf Stenestrand, Lars Wallentin and Bo Lagerqvist for the SCAAR study.
Proxis Proximal embolic protection in saphenous vein graft and infarct PCI Dan Blackman Leeds General Infirmary Advanced Angioplasty 2006.

Proxis Proximal embolic protection in saphenous vein graft and infarct PCI Dan Blackman Leeds General Infirmary Advanced Angioplasty 2006.
ICE 2009 1 Hellenic PCI Registry Organization - Structure - Directions - Initial Recordings Georgios I. Papaioannou, MD,

ICE Hellenic PCI Registry Organization - Structure - Directions - Initial Recordings Georgios I. Papaioannou, MD,
CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.

CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.
Efficacy of high dose atorvaSTATIN loading before primary percutaneous coronary intervention in ST Elevation Myocardial Infarction (STATIN STEMI) Jung-Sun.

Efficacy of high dose atorvaSTATIN loading before primary percutaneous coronary intervention in ST Elevation Myocardial Infarction (STATIN STEMI) Jung-Sun.
Female Gender Is An Independent Predictor Of In-Hospital Mortality After STEMI In The Era of Primary PCI. Insights From The Greater Paris Area PCI Registry.

Female Gender Is An Independent Predictor Of In-Hospital Mortality After STEMI In The Era of Primary PCI. Insights From The Greater Paris Area PCI Registry.
ARMYDA-5 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study Prospective, multicenter, randomized trial investigating influence.

ARMYDA-5 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study Prospective, multicenter, randomized trial investigating influence.

Similar presentations

Ads by Google